Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. (Q45006311)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

0 references

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

3

Patrick Wen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

9

Timothy Cloughesy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Susan M Chang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

John Kuhn

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Harry Greenberg

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

David Schiff

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Charles Conrad

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Karen Fink

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

H Ian Robins

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Jeffrey Razier

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Kenneth Hess

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Janet Dancey

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Michael D Prados

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

North American Brain Tumor Consortium And The National Cancer Institute

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 November 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

427-435

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15292713%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1023/b:drug.0000036685.72140.03

31 December 2019

exact match

0 references

cites work

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

1 reference

12 December 2020

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

12 December 2020

PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)

1 reference

12 December 2020

Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase

1 reference

12 December 2020

A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling

1 reference

12 December 2020

Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

1 reference

12 December 2020

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

1 reference

12 December 2020

Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis.

1 reference

12 December 2020

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

12 December 2020

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

1 reference

12 December 2020

Pten signaling in gliomas

1 reference

12 December 2020

TOR, a central controller of cell growth

1 reference

12 December 2020

Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.

1 reference

12 December 2020

Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.

1 reference

12 December 2020

Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

1 reference

12 December 2020

Targeting mTOR signaling for cancer therapy

1 reference

12 December 2020

Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers

1 reference

12 December 2020